A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

Summary

This is a multi-center, open-label study for eligible participants who were actively participating in the BPS-314d-MR-PAH-302 double-blind study (NCT01908699) at the time the study was concluded. This open-label extension (OLE) study will evaluate the safety, tolerability, and efficacy of long-term treatment with esuberaprost sodium tablets (Beraprost Sodium 314d Modified Release tablets).

Timeline

Start

2018-12-10

Primary completion

2019-07-20

Completion

2019-07-20

Outcome

Outcome not reported

Stopped: “The pivotal study, BPS-314d-MR-PAH-302 (NCT01908699), failed to demonstrate efficacy.”

Drugs

Indications